Serum proteins in prostatic cancer III. Relationship of levels of immunoglobulins and complement to clinical stage of disease

Richard J. Ablin

doi:10.1016/0090-4295(76)90559-8

Serum proteins in prostatic cancer III. Relationship of levels of immunoglobulins and complement to clinical stage of disease

Richard J. Ablin

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

The relationship between the level of the three major serum immunoglobulins, IgG, IgA, and IgM and of the third component of complement (C′) C′3 (B _1A-globulin) and the clinical Stage of prostatic cancer was evaluated. While, statistically significant (P < 0.05) differences in the levels of these proteins compared with their levels in patients with benign prostatic hypertrophy (applied only to the study of C′3) and healthy adults were observed, the levels of these proteins in each of the Stages evaluated were not significantly different from each other. The absence of a correlation between the Stage of disease and the levels of these humorally mediated effectors of immunologic responsiveness is in keeping with observations of cell-mediated effectors of immunologic responsiveness in prostatic cancer patients. Observation of the association of prostatic cancer with a deficiency of B-cell function and of C′3 is noted.

Original language	English (US)
Pages (from-to)	39-47
Number of pages	9
Journal	Urology
Volume	7
Issue number	1
DOIs	https://doi.org/10.1016/0090-4295(76)90559-8
State	Published - Jan 1976
Externally published	Yes

ASJC Scopus subject areas

Urology

Access to Document

10.1016/0090-4295(76)90559-8

Cite this

@article{a58189ba7d2e4978a29fce4560fad4ef,

title = "Serum proteins in prostatic cancer III. Relationship of levels of immunoglobulins and complement to clinical stage of disease",

abstract = "The relationship between the level of the three major serum immunoglobulins, IgG, IgA, and IgM and of the third component of complement (C′) C′3 (B 1A-globulin) and the clinical Stage of prostatic cancer was evaluated. While, statistically significant (P < 0.05) differences in the levels of these proteins compared with their levels in patients with benign prostatic hypertrophy (applied only to the study of C′3) and healthy adults were observed, the levels of these proteins in each of the Stages evaluated were not significantly different from each other. The absence of a correlation between the Stage of disease and the levels of these humorally mediated effectors of immunologic responsiveness is in keeping with observations of cell-mediated effectors of immunologic responsiveness in prostatic cancer patients. Observation of the association of prostatic cancer with a deficiency of B-cell function and of C′3 is noted.",

author = "Ablin, {Richard J.}",

note = "Funding Information: *Experimental phases of the present study were completed and supported in part b,y a grant from the John A. Hartford Foundation, Inc., during author{\textquoteright}s previous appointment as Consultant and Director, Division of Immunology, Millard Fillmore Hospital, Buffalo, New York.",

year = "1976",

month = jan,

doi = "10.1016/0090-4295(76)90559-8",

language = "English (US)",

volume = "7",

pages = "39--47",

journal = "Urology",

issn = "0090-4295",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Serum proteins in prostatic cancer III. Relationship of levels of immunoglobulins and complement to clinical stage of disease

AU - Ablin, Richard J.

N1 - Funding Information: *Experimental phases of the present study were completed and supported in part b,y a grant from the John A. Hartford Foundation, Inc., during author’s previous appointment as Consultant and Director, Division of Immunology, Millard Fillmore Hospital, Buffalo, New York.

PY - 1976/1

Y1 - 1976/1

N2 - The relationship between the level of the three major serum immunoglobulins, IgG, IgA, and IgM and of the third component of complement (C′) C′3 (B 1A-globulin) and the clinical Stage of prostatic cancer was evaluated. While, statistically significant (P < 0.05) differences in the levels of these proteins compared with their levels in patients with benign prostatic hypertrophy (applied only to the study of C′3) and healthy adults were observed, the levels of these proteins in each of the Stages evaluated were not significantly different from each other. The absence of a correlation between the Stage of disease and the levels of these humorally mediated effectors of immunologic responsiveness is in keeping with observations of cell-mediated effectors of immunologic responsiveness in prostatic cancer patients. Observation of the association of prostatic cancer with a deficiency of B-cell function and of C′3 is noted.

AB - The relationship between the level of the three major serum immunoglobulins, IgG, IgA, and IgM and of the third component of complement (C′) C′3 (B 1A-globulin) and the clinical Stage of prostatic cancer was evaluated. While, statistically significant (P < 0.05) differences in the levels of these proteins compared with their levels in patients with benign prostatic hypertrophy (applied only to the study of C′3) and healthy adults were observed, the levels of these proteins in each of the Stages evaluated were not significantly different from each other. The absence of a correlation between the Stage of disease and the levels of these humorally mediated effectors of immunologic responsiveness is in keeping with observations of cell-mediated effectors of immunologic responsiveness in prostatic cancer patients. Observation of the association of prostatic cancer with a deficiency of B-cell function and of C′3 is noted.

UR - http://www.scopus.com/inward/record.url?scp=0017263541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017263541&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(76)90559-8

DO - 10.1016/0090-4295(76)90559-8

M3 - Article

C2 - 1246767

AN - SCOPUS:0017263541

SN - 0090-4295

VL - 7

SP - 39

EP - 47

JO - Urology

JF - Urology

IS - 1

ER -

Serum proteins in prostatic cancer III. Relationship of levels of immunoglobulins and complement to clinical stage of disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this